Use access key #2 to skip to page content.
$2.41 0.02 (0.84%)
7/3/2008 1:00 PM

Cell Genesys, Inc. (CEGE)

CAPS Rating:
***

A biotechnology company focused on the development and commercialization of novel biological therapies for patients with cancer.

View All Commentary (CEGE)

Recs

0

Avatar RhoWidget (< 20) Submitted: 5/11/08 9:23 AM : Outperform Start Price: $3.98 CEGE Score: -30.15

FDA approval for GVAX by 2nd quarter CY09.

Report this Post Replies: 0 | Reply

Featured Broker Partners